z-logo
open-access-imgOpen Access
Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
Author(s) -
Camille Jubelin,
Javier Muñoz-García,
Denis Cochonneau,
Emilie Moranton,
Marie-Françoise Heymann,
Dominique Heymann
Publication year - 2022
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.130
Subject(s) - osteosarcoma , cancer stem cell , cancer , bone cancer , disease , cancer research , mesenchyme , medicine , drug resistance , sarcoma , pathology , biology , oncology , mesenchymal stem cell , genetics
Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and adolescents in whom sarcomas are the second most common malignant entities. Osteosarcoma is the main primary bone tumor in adolescents and young adults and is characterized by a high propensity to induce distant metastatic foci and become multi-drug resistant. The innate and acquired resistance of osteosarcoma can be explained by high histological heterogeneity and genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged. This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and therapeutic failure. Although CSCs remain controversial, many elements are in favor of them playing a role in the development of the drug resistance profile. The present review gives a brief overview of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug resistance profile of these rare oncological entities. Their use as promising therapeutic targets is discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here